Plant Comparison
Hawthorn vs Common coltsfoot
A side-by-side comparison of two medicinal plants — every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.
At a glance
Hawthorn and Common coltsfoot: they share 4 indicated uses (arthritis / joint pain, inflammation (general), insomnia / sleeplessness, …); 2 pharmacological actions in common.
Evidence face-off — shared uses
| Condition | Hawthorn | Common coltsfoot | Verdict |
|---|---|---|---|
| Arthritis / joint pain | 1/10 | 1/10 | Comparable evidence |
| Inflammation (general) | 1/10 | 2/10 | Comparable evidence |
| Insomnia / sleeplessness | 1/10 | 1/10 | Comparable evidence |
| Skin irritation | 1/10 | 1/10 | Comparable evidence |
Evidence scores (1–10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.
Key Constituents
Principal cardioprotective and antioxidant polyphenols characterised by chemical profiling of leaf, flower and fruit.
Contribute to the vasoactive and antioxidant effects, the basis for extract standardisation.
Hepatotoxic constituents that are the central safety concern for this plant; regulatory limits and PA-controlled/PA-reduced products exist specifically because of these compounds.
Demulcent polysaccharide contributing to the traditional soothing action on irritated airways.
Pharmacological Actions
Traditional & Indicated Uses
inferred from anti-inflammatory action
inferred from anticancer action
inferred from anti-inflammatory action
inferred from sedative action
inferred from anti-inflammatory action
inferred from anti-inflammatory action
inferred from sedative action
Safety, Cautions & Contraindications
Generally well tolerated. Hawthorn should not replace prescribed cardiac medications without medical supervision. May potentiate the effects of cardiac glycosides (digoxin), antihypertensive drugs, and coronary dilators. Not recommended during pregnancy and breastfeeding due to insufficient safety data. Mild side effects (nausea, dizziness, GI upset) occasionally reported.
Duke (2002) rates hawthorn as +++ — one of the most clinically supported cardiovascular herbs. Clinical evidence (score 2) supports its use for decreasing cardiac output (NYHA functional Stage II heart failure), as recognized by Commission E. Key activities include vasodilation, positive inotropic effects, and antioxidant protection of vascular tissue. Dose: 160–900 mg standardized leaf/flower extract (containing 18.75% oligomeric proanthocyanidins) daily. Duke emphasizes that hawthorn should not replace conventional heart failure therapy, and therapeutic effects may take 4–8 weeks to emerge. Mild interactions with cardiac glycosides (digitalis) are possible (Duke, 2002).
Safety notes (contraindications, interactions, pregnancy/lactation notes, adverse effects, dose-duration cautions) Important: Coltsfoot naturally contains pyrrolizidine alkaloids (PAs)—plant chemicals that can damage the liver and may increase cancer risk with enough exposure (EMA, 2021; Kopp et al., 2020).
Because of this, European regulators set very strict limits for PA exposure from herbal products (EMA, 2021).
Many safety-focused herbal references recommend avoiding homemade/internal coltsfoot use, unless the product is specifically made to be PA-controlled / PA-reduced (EMA, 2021).
Avoid internal use if you are pregnant or breastfeeding, have liver disease, or for children—these groups are treated as “sensitive” in PA risk guidance (EMA, 2021).
Medication caution: if you take medicines that stress the liver (some prescription drugs can), it’s extra important to avoid unregulated PA exposure (general PA risk logic; consult a clinician) (EMA, 2021).
Topical use may still carry PA considerations; EMA discusses limits and recommends use only on intact skin for PA-containing products (EMA, 2021).
Duke (2002) provides clinical support (score 2) for coltsfoot's anti-inflammatory and expectorant effects, explaining its traditional use in bronchitis and coughs. However, the plant contains hepatotoxic pyrrolizidine alkaloids (PAs), and Duke notes a carcinogenic score (1) — a critical safety concern. Commission E has placed restrictions on coltsfoot use, recommending maximum internal use of 4–6 weeks per year and avoiding use in pregnancy, lactation, and in children under 12. Duke rates its overall safety as low (+) and emphasizes that preparations free of PAs are preferred (Duke, 2002).
External Ids
Botanical Description
Small deciduous tree or large shrub, densely thorny, with deeply lobed, glossy leaves (more deeply cut than midland hawthorn). Clusters of small, five-petalled white flowers with a strong, musky scent appear in spring ('May blossom'), followed by small red berries (haws), each containing a single seed (nutlet) - the origin of the species name monogyna.[4]
Low perennial herb notable for flowering before its leaves appear: solitary, bright yellow, dandelion-like flower heads emerge on scaly pinkish stalks in very early spring, followed later by large, hoof-shaped (heart-shaped with angular teeth), white-woolly-backed leaves arising directly from the creeping rhizome.[11]
Habitat
One of the commonest hedgerow and scrub trees of Europe, growing in hedgerows, woodland edges, scrub and pasture on a wide range of soils; native to Europe, North Africa and Western Asia.[4]
Grows on disturbed, damp or clay-rich waste ground, riverbanks, railway embankments and bare soil; native to Europe, North Africa and temperate Asia and naturalised in North America.[11]
Harvesting
Flowers are picked as they open in May, leaves are picked with the young flowering shoots, and the ripe red berries (haws) are gathered in autumn after the first frosts soften them slightly; all three parts are traditionally combined.[4]
Flowers are gathered in very early spring before the leaves appear; leaves are gathered later in the season once expanded. Given the plant's pyrrolizidine alkaloid content, harvesting from a positively confirmed patch (not a look-alike) and preferring PA-tested commercial material for internal use is strongly advised.[2]
Traditional Uses
Common hawthorn shares the same long cardiovascular and calming tradition as midland hawthorn, used across European herbal medicine as a heart tonic for mild circulatory complaints, palpitations and nervous tension, and remains one of the most clinically studied cardiovascular botanicals.[4]
Coltsfoot has an ancient European and Chinese tradition, reflected in its Latin name (tussis = cough), as an expectorant and demulcent remedy for coughs, bronchitis and irritated airways; because of its pyrrolizidine alkaloid content, contemporary use is restricted to short courses of PA-controlled preparations under regulatory limits (see contraindications).[1, 2, 12]
Preparations
Leaf-and-flower extract standardised to flavonoid or procyanidin content, taken as tablets or capsules; the best-studied clinical form.
Commercially prepared, pyrrolizidine-alkaloid-tested extract or syrup, the only form recommended for internal use given the plant's natural PA content.
Dried flower or leaf infused in hot water; traditional but subject to strict duration/PA-content limits under EU herbal regulation.
Dosage
The EU herbal monograph on Crataegus spp., folium cum flore gives dry extracts in divided daily doses of 240-900 mg (single dose 80-450 mg) or, for one quantified extract, 570-1750 mg daily (single dose 190-350 mg), in adults and elderly. If symptoms persist longer than 2 weeks a doctor should be consulted, and hawthorn is never used as a substitute for prescribed heart medication without medical supervision. Educational reference only, not a prescription.
The EU herbal monograph gives 1-2 g of the comminuted leaf and flower in 150 mL of boiling water as an infusion, up to 4 times daily (maximum 6 g daily), in adults and elderly. Educational reference only, not a prescription.
EU regulatory guidance restricts internal use to PA-controlled preparations. The EMA public statement on unsaturated pyrrolizidine alkaloids records a maximum daily intake for internal use of 1 microgram of PAs for at most 6 weeks per year, or 0.1 microgram per day with no duration limit; for cutaneous use the limits are 100 micrograms for at most 6 weeks per year, or 10 micrograms without a duration limit. Not for use in pregnancy, breastfeeding, or children. Note that these are limits on PA intake, not a herb dose — no EMA monograph exists for Tussilago farfara, so there is no official posology for the herb itself. Educational reference only, not a prescription — consult a qualified practitioner and prefer tested commercial products.
References
Drug Class Interactions
Not documented
Lookalikes Review
Dangerous Lookalikes
Not documented
References & Sources
- Ez-Zahra Amrati, F., Mssillou, I., Boukhira, S., Djiddi Bichara, M. et al (2024) 'Phenolic Composition of Crataegus monogyna Jacq. Extract and Its Anti-Inflammatory, Hepatoprotective, and Antileukemia Effects', Pharmaceuticals (Basel), 17(6), pp. 786. doi:10.3390/ph17060786 Preclinical
https://doi.org/10.3390/ph17060786 - Lis, M., Szczypka, M., Suszko-Pawłowska, A., Sokół-Łętowska, A. et al (2019) 'Hawthorn (Crataegus monogyna) Phenolic Extract Modulates Lymphocyte Subsets and Humoral Immune Response in Mice', Planta Medica, 86(2), pp. 160-168. doi:10.1055/a-1045-5437 Preclinical
https://doi.org/10.1055/a-1045-5437 - Paun, G., Neagu, E., Albu, C., Alecu, A. et al (2024) 'Antioxidant and Antidiabetic Activity of Crataegus monogyna L. and Cornus mas Fruit Extracts', Molecules, 29(15), pp. 3595. doi:10.3390/molecules29153595 Preclinical
https://doi.org/10.3390/molecules29153595 - Nabavi, S.F., Habtemariam, S., Ahmed, T., Sureda, A., Daglia, M. and Sobarzo-Sanchez, E (2015) 'Polyphenolic Composition of Crataegus monogyna Jacq.: From Chemistry to Medical Applications', Nutrients, 7(9), pp. 7708-7728. doi:10.3390/nu7095361 Meta-analysis / review
https://doi.org/10.3390/nu7095361 - Belabdelli, F., Bekhti, N., Piras, A., Benhafsa, F.M., Ilham, M. and Adil, S (2021) 'Chemical composition, antioxidant and antibacterial activity of Crataegus monogyna leaves' extracts', Natural Product Research, 36(12), pp. 3234-3239. doi:10.1080/14786419.2021.1958215 Preclinical
https://doi.org/10.1080/14786419.2021.1958215 - Jalali, A.S., Hasanzadeh, S. and Malekinejad, H (2012) 'Crataegus monogyna aqueous extract ameliorates cyclophosphamide-induced toxicity in rat testis: stereological evidences', Acta Medica Iranica, 50(1), pp. 1-8. Preclinical
https://scholar.google.com/scholar?q=Crataegus%20monogyna%20aqueous%20extract%20ameliorates%20cyclophosphamide-induced%20toxicity%20in%20rat%20testis%3A%20stereological%20evidences - Martin-Garcia, B., Razola-Diaz, M.D.C., Gomez-Caravaca, A.M., Benitez, G. and Verardo, V (2021) 'Setup of an Ultrasonic-Assisted Extraction to Obtain High Phenolic Recovery in Crataegus monogyna Leaves', Molecules, 26(15), pp. 4536. doi:10.3390/molecules26154536 Preclinical
https://doi.org/10.3390/molecules26154536 - Arslan, R., Bektas, N., Bor, Z. and Sener, E (2014) 'Evaluation of the antithrombotic effects of Crataegus monogyna and Crataegus davisii in the carrageenan-induced tail thrombosis model', Pharmaceutical Biology, 53(2), pp. 275-279. doi:10.3109/13880209.2014.914957 Preclinical
https://doi.org/10.3109/13880209.2014.914957 - Edwards, J.E., Brown, P.N., Talent, N., Dickinson, T.A. and Shipley, P.R (2012) 'A review of the chemistry of the genus Crataegus', Phytochemistry, 79, pp. 5-26. doi:10.1016/j.phytochem.2012.04.006 Meta-analysis / review
https://doi.org/10.1016/j.phytochem.2012.04.006 - Jarzycka, A., Lewinska, A., Gancarz, R. and Wilk, K.A (2013) 'Assessment of extracts of Helichrysum arenarium, Crataegus monogyna, Sambucus nigra in photoprotective UVA and UVB; photostability in cosmetic emulsions', Journal of Photochemistry and Photobiology B: Biology, 128, pp. 50-57. doi:10.1016/j.jphotobiol.2013.07.029 Preclinical
https://doi.org/10.1016/j.jphotobiol.2013.07.029 - Lucconi, G., Chlapanidas, T., Martino, E., Gaggeri, R., Perteghella, S. and Rossi, D (2013) 'Formulation of microspheres containing Crataegus monogyna Jacq. extract with free radical scavenging activity', Pharmaceutical Development and Technology, 19(1), pp. 65-72. doi:10.3109/10837450.2012.752387 Preclinical
https://doi.org/10.3109/10837450.2012.752387 - Zorniak, M., Szydlo, B. and Krzeminski, T.F (2017) 'Crataegus special extract WS 1442: up-to-date review of experimental and clinical experiences', Journal of Physiology and Pharmacology, 68(4), pp. 521-526. Meta-analysis / review
https://scholar.google.com/scholar?q=Crataegus%20special%20extract%20WS%201442%3A%20up-to-date%20review%20of%20experimental%20and%20clinical%20experiences - European Medicines Agency (2016) 'European Union herbal monograph on Crataegus spp., folium cum flore'. Traditional / reference
https://scholar.google.com/scholar?q=European%20Union%20herbal%20monograph%20on%20Crataegus%20spp.%2C%20folium%20cum%20flore - Pittler, M.H., Guo, R. and Ernst, E (2008) 'Hawthorn extract for treating chronic heart failure'. Traditional / reference
https://scholar.google.com/scholar?q=Hawthorn%20extract%20for%20treating%20chronic%20heart%20failure - Royal Botanic Gardens, Kew (n.d.). Available at: https://powo.science.kew.org Traditional / reference
https://powo.science.kew.org - Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition - Tankanow, R., Tamer, H.R., Streetman, D.S., Smith, S.G., Welton, J.L., Annesley, T., Aaronson, K.D. and Bleske, B.E (2003) 'Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha)', Journal of Clinical Pharmacology, 43(6), pp. 637-642. doi:10.1177/0091270003253417 Randomized trial
https://doi.org/10.1177/0091270003253417 - Pittler, M.H., Guo, R. and Ernst, E (2008) 'Hawthorn extract for treating chronic heart failure', Cochrane Database of Systematic Reviews, 2008(1), pp. CD005312. doi:10.1002/14651858.CD005312.pub2 Meta-analysis / review
https://doi.org/10.1002/14651858.CD005312.pub2 - Pittler, M.H., Guo, R. and Ernst, E (2008) 'Hawthorn extract for treating chronic heart failure', Cochrane Database of Systematic Reviews, 2008(1), pp. CD005312. doi:10.1002/14651858.CD005312.pub2 Meta-analysis / review
https://doi.org/10.1002/14651858.CD005312.pub2 - Ghasemzadeh Rahbardar, M. and Hosseinzadeh, H (2024) 'Therapeutic potential of hypnotic herbal medicines: A comprehensive review', Phytotherapy Research, 38(6), pp. 3037-3059. doi:10.1002/ptr.8201 Meta-analysis / review
https://doi.org/10.1002/ptr.8201 - Block, K.I., Gyllenhaal, C. and Mead, M.N (2004) 'Safety and efficacy of herbal sedatives in cancer care', Integrative Cancer Therapies, 3(2), pp. 128-148. doi:10.1177/1534735404265003 Meta-analysis / review
https://doi.org/10.1177/1534735404265003
- Ahmad, I., Kudaibergenova, B., Ahmad, M. and others (2025) 'Coltsfoot (Tussilago farfara L.; Asteraceae): modern methods of extraction, phytochemistry, nanoparticles synthesis, ethnopharmacology, and biological activities', Natural Product Research, pp. 1-20. doi:10.1080/14786419.2025.2548616 Traditional / reference
https://doi.org/10.1080/14786419.2025.2548616 - Chen, S., Dong, L., Quan, H., Zhou, X. and others (2020) 'A review of the ethnobotanical value, phytochemistry, pharmacology, toxicity and quality control of Tussilago farfara L. (coltsfoot)', Journal of Ethnopharmacology, 267, pp. 113478. doi:10.1016/j.jep.2020.113478 Traditional / reference
https://doi.org/10.1016/j.jep.2020.113478 - Feng, J., Zhang, Y., Qin, X., Gao, T. and others (2022) 'Novel Quinic Acid Glycerates from Tussilago farfara Inhibit Polypeptide GalNAc-Transferase', ChemBioChem, 23(3), pp. e202100539. doi:10.1002/cbic.202100539 Preclinical
https://doi.org/10.1002/cbic.202100539 - Zhao, J., Evangelopoulos, D., Bhakta, S., Gray, A.I. and Seidel, V (2014) 'Antitubercular activity of Arctium lappa and Tussilago farfara extracts and constituents', Journal of Ethnopharmacology, 155(1), pp. 796-800. doi:10.1016/j.jep.2014.06.034 Preclinical
https://doi.org/10.1016/j.jep.2014.06.034 - Avila, C., Breakspear, I., Hawrelak, J., Salmond, S. and Evans, S (2020) 'A systematic review and quality assessment of case reports of adverse events for borage (Borago officinalis), coltsfoot (Tussilago farfara) and comfrey (Symphytum officinale)', Fitoterapia, 142, pp. 104519. doi:10.1016/j.fitote.2020.104519 Meta-analysis / review
https://doi.org/10.1016/j.fitote.2020.104519 - Lee, J., Park, S., Kim, M.J., Kwon, S.J. and others (2019) 'Sesquiterpenoids from Tussilago farfara Flower Bud Extract for the Eco-Friendly Synthesis of Silver and Gold Nanoparticles Possessing Antibacterial and Anticancer Activities', Nanomaterials (Basel), 9(6), pp. 819. doi:10.3390/nano9060819 Preclinical
https://doi.org/10.3390/nano9060819 - Bota, V.B., Neamtu, A.A., Olah, N.K., Chiselita, O. and others (2022) 'A Comparative Analysis of the Anatomy, Phenolic Profile, and Antioxidant Capacity of Tussilago farfara L. Vegetative Organs', Plants (Basel), 11(13), pp. 1663. doi:10.3390/plants11131663 Preclinical
https://doi.org/10.3390/plants11131663 - Boucher, M.A., Cote, H., Pichette, A., Ripoll, L. and Legault, J (2020) 'Chemical composition and antibacterial activity of Tussilago farfara (L.) essential oil from Quebec, Canada', Natural Product Research, 34(4), pp. 545-548. doi:10.1080/14786419.2018.1489384 Preclinical
https://doi.org/10.1080/14786419.2018.1489384 - Li, Z.Y., Zhang, J., Zhang, Y.B., Yang, X.W. and others (2022) 'Polyhydroxylated eudesmane sesquiterpenoids and sesquiterpenoid glucoside from the flower buds of Tussilago farfara', Chinese Journal of Natural Medicines, 20(4), pp. 301-308. doi:10.1016/S1875-5364(21)60120-6 Preclinical
https://doi.org/10.1016/S1875-5364(21)60120-6 - Jang, H., Lee, J.W., Lee, C., Jin, Q. and others (2016) 'Sesquiterpenoids from Tussilago farfara inhibit LPS-induced nitric oxide production in macrophage RAW 264.7 cells', Archives of Pharmacal Research, 39(1), pp. 127-132. doi:10.1007/s12272-015-0667-7 Preclinical
https://doi.org/10.1007/s12272-015-0667-7 - Royal Botanic Gardens, Kew (n.d.). Available at: https://powo.science.kew.org Traditional / reference
https://powo.science.kew.org - Westendorf, J., Czok, G., Marquardt, R., Nausner, M., Krauer, B. and Paul, H.L (1988) 'Pyrrolizidine alkaloid content of Tussilago farfara plants from different regions and preparations', pp. 903--909. Traditional / reference
https://scholar.google.com/scholar?q=Pyrrolizidine%20alkaloid%20content%20of%20Tussilago%20farfara%20plants%20from%20different%20regions%20and%20preparations - European Medicines Agency (HMPC) (2021) 'Public statement on the use of herbal medicinal products containing toxic, unsaturated pyrrolizidine alkaloids (PAs), including recommendations regarding contamination of herbal medicinal products with PAs, Revision 1'. Available at: https://www.ema.europa.eu/en/documents/public-statement/public-statement-use-herbal-medicinal-products-containing-toxic-unsaturated-pyrrolizidine-alkaloids-pas-including-recommendations-regarding-contamination-herbal-medicinal-products-pyrrolizidine_en.pdf Traditional / reference
https://www.ema.europa.eu/en/documents/public-statement/public-statement-use-herbal-medicinal-products-containing-toxic-unsaturated-pyrrolizidine-alkaloids-pas-including-recommendations-regarding-contamination-herbal-medicinal-products-pyrrolizidine_en.pdf - Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition - Sperl, W. and Stuppner, H. and Gassner, I. and Judmaier, W. and Dietze, O. and Vogel, W (1995) 'Reversible hepatic veno-occlusive disease in an infant after consumption of pyrrolizidine-containing herbal tea', European Journal of Pediatrics, 154(2), pp. 112-6. doi:10.1007/BF01991912 Clinical study
https://doi.org/10.1007/BF01991912
Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only — not medical advice. Always consult a qualified practitioner before using medicinal plants.